284 related articles for article (PubMed ID: 25995130)
1. Cost-Effectiveness of Proton Pump Inhibitor Co-Therapy in Patients Taking Aspirin for Secondary Prevention of Ischemic Stroke.
Takabayashi N; Murata K; Tanaka S; Kawakami K
Pharmacoeconomics; 2015 Oct; 33(10):1091-100. PubMed ID: 25995130
[TBL] [Abstract][Full Text] [Related]
2. Gastroprotection in low-dose aspirin users for primary and secondary prevention of ACS: results of a cost-effectiveness analysis including compliance.
de Groot NL; van Haalen HG; Spiegel BM; Laine L; Lanas A; Focks JJ; Siersema PD; van Oijen MG
Cardiovasc Drugs Ther; 2013 Aug; 27(4):341-57. PubMed ID: 23417566
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
Saini SD; Fendrick AM; Scheiman JM
Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility of aspirin and proton pump inhibitors for primary prevention.
Earnshaw SR; Scheiman J; Fendrick AM; McDade C; Pignone M
Arch Intern Med; 2011 Feb; 171(3):218-25. PubMed ID: 21325111
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness of Gastroprotection with Proton Pump Inhibitors in Older Low-Dose Acetylsalicylic Acid Users in the Netherlands.
Chau SH; Sluiter RL; Kievit W; Wensing M; Teichert M; Hugtenburg JG
Drugs Aging; 2017 May; 34(5):375-386. PubMed ID: 28361278
[TBL] [Abstract][Full Text] [Related]
7. The budget impact of using enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg to prevent recurrent cardiovascular events.
Zhang W; Han Y; Fort JG; Schofield D; Tursi JP
J Med Econ; 2017 Jun; 20(6):592-598. PubMed ID: 28145783
[TBL] [Abstract][Full Text] [Related]
8. A comparison of aspirin and clopidogrel with or without proton pump inhibitors for the secondary prevention of cardiovascular events in patients at high risk for gastrointestinal bleeding.
Hsiao FY; Tsai YW; Huang WF; Wen YW; Chen PF; Chang PY; Kuo KN
Clin Ther; 2009 Sep; 31(9):2038-47. PubMed ID: 19843493
[TBL] [Abstract][Full Text] [Related]
9. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
10. [Incremental cost-effectiveness of dipyridamole + acetylsalicylic acid in secondary prevention of ischemic noncardioembolic stroke].
Claes C; Mittendorf T; Grond M; von der Schulenburg JM
Med Klin (Munich); 2008 Nov; 103(11):778-87. PubMed ID: 19165429
[TBL] [Abstract][Full Text] [Related]
11. Predictors and time trends in clopidogrel and proton pump inhibitor coprescription with low-dose acetylsalicylic acid.
Cea Soriano L; Bueno H; Johansson S; García Rodríguez LA
Pharmacoepidemiol Drug Saf; 2012 May; 21(5):463-9. PubMed ID: 22298501
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
13. Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Sáez ME; González-Pérez A; Johansson S; Nagy P; Rodríguez LA
J Cardiovasc Pharmacol Ther; 2015 Jul; 20(4):378-86. PubMed ID: 25501499
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
15. Effect of low-dose proton pump inhibitor on preventing upper gastrointestinal bleeding in chronic kidney disease patients receiving aspirin.
Lim H; Kim JH; Baik GH; Park JW; Kang HS; Moon SH; Park CK
J Gastroenterol Hepatol; 2015 Mar; 30(3):478-84. PubMed ID: 25252119
[TBL] [Abstract][Full Text] [Related]
16. Effect of baseline gastrointestinal risk and use of proton pump inhibitors on frequency of discontinuation of aspirin for secondary cardiovascular prevention in United kingdom primary care.
Martín Merino E; Johansson S; Nagy P; García Rodríguez LA
Am J Cardiol; 2013 Oct; 112(8):1075-82. PubMed ID: 23831164
[TBL] [Abstract][Full Text] [Related]
17. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Wu B; Kun L; Liu X; He B
Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
